| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 557 | 1.924 | 4.751 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 557 | 4.093 | 4.751 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 2.825 | 5.234 | 5.937 | 2.122 | 1.722 | 1.636 | 149 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | -2.269 | -1.141 | -1.186 | -2.122 | -1.722 | -1.636 | -149 | 0 | 0 | 0 |
| Net Profit/Loss - EUR | -2.285 | -1.256 | -1.329 | -2.122 | -1.722 | -1.636 | -149 | 0 | 0 | 0 |
| Employees | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 0 |
Check the financial reports for the company - Medstar 2000-Study Division Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 168 | 111 | 209 | 130 | 187 | 88 | 89 | 89 | 89 | 89 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 90 | 88 | 86 | 91 | 92 | 92 | 92 | 92 |
| Cash | 168 | 111 | 119 | 42 | 100 | -3 | -3 | -3 | -3 | -3 |
| Shareholders Funds | -7.746 | -8.923 | -10.101 | -12.037 | -13.527 | -14.906 | -14.724 | -14.770 | -14.725 | -14.643 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 7.913 | 9.034 | 10.310 | 12.167 | 13.713 | 14.995 | 14.814 | 14.860 | 14.815 | 14.732 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8541
|
|||||||||
Comments - Medstar 2000-Study Division Srl